1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
RVL Pharmaceuticals plc

RVL Pharmaceuticals plc

RVLPQ
RVL Pharmaceuticals plcUS flagOther OTC
0.00
USD
- -
- -
1,114.00Market Cap
RVL Pharmaceuticals plc
RVLPQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
TTM
FRC
5.1
5.73
5.82
4.58
0.46
0.26
0.55
0.38
Revenue per Share
-0.98
-0.96
-2.42
-5.17
-1.31
-0.96
-0.58
-0.7
Basic EPS, GAAP
-1.42
1.19
0.74
0.56
0.24
-0.84
-0.43
-0.49
Free Cash Flow per Basic Share
0.54
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-2.24
-7.11
-7.45
-7.67
-6.33
-6.18
Book Value per Share
-9.08
-7.86
-4.58
-2.68
0.05
-0.09
-0.21
-0.4
Tangible Book Value per Share
43
43
45
52
61
67
90
98
Basic Weighted Avg Shares
218
246
264
240
28
18
50
37
Sales/Revenue/Turnover
-1
8.51
2.16
1.27
-222.4
-460.03
-91.87
-118.02
Operating Margin (%)
24
46
82
57
21
8
- -
- -
Depreciation Expense
-42
-41
-110
-271
-80
-65
-52
-68
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-19.14
-16.74
-41.59
-112.86
-286.68
-370.95
-103.96
-184.91
Profit Margin (%)
-24
-10
58
97
117
39
37
-43
Working Capital
324
314
267
271
220
44
56
- -
LT Debt
465
436
384
115
94
77
51
16
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
2
4
58
LT Borrowings
56
53
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
101
107
55

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
57
38
26
Cash, Cash Equivalents & STI
45
33
19
Accounts Receivable, Net
1
- -
1
Inventories
1
- -
1
Total Current Liabilities
20
16
68
Payables & Accruals
12
8
7
ST Debt
2
4
58
Deferred Revenue
2
2
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-30.37%
-33.41%
Free Cash Flow
- -
-123.96%
-31.77%
Net Income, GAAP
- -
40.83%
-20.38%
Sales/Revenue/Turnover
- -
11.41%
184.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
12
2
3
18
2022
21
8
10
10
50
2023
9
8
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.15
-0.28
-0.28
-0.24
-0.96
2022
-0.08
-0.14
-0.16
-0.18
-0.58
2023
-0.12
-0.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Sequenom Inc. (SQNM)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
I-Tech AB (ITECH.ST)
Selecta Biosciences, Inc. (SELB)
Idorsia Ltd (0RQE.L)
Samsrita Labs Ltd. (SAMSRITA.BO)
Business
RVL Pharmaceuticals plc (RVLPQ) is a specialty pharmaceutical company focused on developing and commercializing ophthalmic prescription products for medical conditions including dry eye disease and abnormalities of the eyelids. The company offers Uplizna (a self-microemulsifying drug delivery system formulation of oxymetazoline hydrochloride ophthalmic solution, 0.1%), an alpha-1 adrenergic receptor agonist indicated for the treatment of acquired blepharoptosis in adults; and commercializes other branded ophthalmic products such as KPI-12, which targets meibomian gland dysfunction in adult patients with dry eye disease associated with meibomian gland dysfunction; along with additional offerings in the dry eye and eyelid disorder therapeutic categories. Founded in 2016 and headquartered in Bridgewater, New Jersey, RVL operates primarily in the United States with a focus on ophthalmology markets, targeting healthcare providers and patients requiring treatments for eye-related conditions.